Trial Profile
A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 14 Mar 2024
Price :
$35
*
At a glance
- Drugs Alectinib (Primary) ; Atezolizumab (Primary) ; Cobimetinib (Primary) ; Entrectinib (Primary) ; Vemurafenib (Primary) ; Bevacizumab; Carboplatin; Cisplatin; Gemcitabine; Pemetrexed
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms B-FAST
- Sponsors Roche
- 24 Oct 2023 Results (n=87) of updated data with longer follow-up, and exploratory correlative ctDNA and biomarker analyses from sub-groups of cohort A presented at the 48th European Society for Medical Oncology Congress
- 08 Sep 2023 This trial has been completed in Germany, according to European Clinical Trials Database record.
- 01 Sep 2022 Primary endpoint (Cohort C: Progression Free Survival (PFS) as Assessed by the Investigator Based on the RECIST v1.1) has not been met according to results published in the Nature Medicine.